For a patient with advanced prostate cancer, the difference between a standard treatment and a targeted radiopharmaceutical can be measured in months of life. The promise of theranostics, which uses radioactive isotopes to both diagnose and treat tumors, is immense. Yet for a clinical trial sponsor in Northern Europe, the most immediate challenge is often a logistical one: securing a reliable, high-quality supply of the short-lived radioisotopes these therapies depend on. A new Swedish startup, Hela Radiopharma AB, is betting that building the region's first privately owned, industrial-scale production hub is the key to unlocking that potential [Hela Radiopharma, January 2026].
The Infrastructure Wedge
Founded in 2024, Hela Radiopharma is not developing a new drug. Its product is infrastructure. The company plans to establish a facility in Stockholm equipped with cyclotrons from Japan's Sumitomo Heavy Industries to produce radioisotopes for positron emission tomography (PET) imaging and therapeutic applications [Hela Radiopharma, January 2026]. This positions it as a contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) for pharmaceutical companies, academic researchers, and healthcare providers. The strategic wedge is geographic and industrial: by creating a local, GMP-certified production node, Hela aims to reduce Northern Europe's dependency on a fragile, centralized global supply chain for these critical medical isotopes.
Why the Bet Could Work
The timing aligns with a significant clinical and commercial tailwind. Theranostics, particularly for cancers like prostate and neuroendocrine tumors, has moved from academic curiosity to a validated treatment pathway with multi-billion dollar commercial products. Each new drug candidate entering clinical development requires a stable isotope supply for trials, a need that often outpaces existing capacity. Hela's stated ambition to become a "Northern European Hub for Theranostics and Targeted Alpha Therapy" directly addresses this bottleneck [Hela Radiopharma, January 2026]. Furthermore, its partnership with an established cyclotron manufacturer, Sumitomo, provides a clear technical roadmap, though the path from equipment plans to a fully validated, regulatory-approved facility is long and capital-intensive.
| Aspect | Hela Radiopharma's Position |
|---|---|
| Core Business | B2B radiopharmaceutical production (CMO/CDMO) |
| Key Technology | Sumitomo HM-20 & MP-30X cyclotrons [Hela Radiopharma, January 2026] |
| Target Customers | Pharma companies, clinical trial sponsors, research orgs, hospitals |
| Geographic Focus | Northern Europe, with a facility planned in Stockholm, Sweden |
| Founding Team | Led by co-founder and Managing Director Liliane Rothoff [LinkedIn] |
The Execution Hurdles
The vision is clear, but the company is at the earliest stages of making it real. Public records show a registered share capital of SEK 25,000 and a team of two employees, indicating a pre-operational entity [Bolagsfakta.se, 2026]. The leap from this foundation to an industrial-scale GMP facility represents a multi-year, nine-figure capital project. The risks are not subtle:
- Regulatory marathon. Building and certifying a radiopharmacy is one of the most heavily regulated endeavors in medicine, requiring approvals from bodies like the Swedish Medical Products Agency and adherence to strict EU Good Manufacturing Practice standards. There is no public evidence yet of submitted applications or site approvals.
- Capital intensity. The company has not disclosed any institutional venture funding. The scale of investment required for cyclotrons, hot cells, quality control labs, and shielding far exceeds typical pre-seed or seed rounds. Securing this capital, likely from specialized healthcare infrastructure funds, is a prerequisite for any physical progress.
- Commercial validation. While the market need is well-documented, Hela has not announced any signed supply agreements or anchor customers. For pharmaceutical partners, committing to a supplier that does not yet have a functioning facility is a significant leap of faith.
For patients with metastatic castration-resistant prostate cancer or advanced neuroendocrine tumors, the standard of care today often involves a sequential series of treatments with diminishing returns. The advent of targeted radiopharmaceuticals like lutetium-177 PSMA-617 has created a new, more precise option, but its availability is constrained by complex production and logistics. Hela Radiopharma's entire thesis rests on the belief that by solving the supply problem locally, it can accelerate the development and delivery of these next-generation therapies across Northern Europe. It is a bet on infrastructure enabling medicine, where success would be measured not in software updates, but in the reliable arrival of a lifesaving dose.
Sources
- [Hela Radiopharma, January 2026] Home | https://www.helaradiopharma.com/
- [LinkedIn] Liliane Rothoff Profile | https://www.linkedin.com/in/liliane-rothoff
- [Bolagsfakta.se, retrieved 2026] Hela Radiopharma Sweden AB | https://www.bolagsfakta.se/5594936402-Hela_Radiopharma_Sweden_AB
- [Report Prime, retrieved 2026] Top 10 Laboratory Cyclotrons Companies | https://www.reportprime.com/laboratory-cyclotrons-r8900/company